Advisory Board and Editors Cancer Biology
Christopher Cooper
Senior Lecturer in Biological Sciences at the University of Huddersfield, since 2015. Previously Junior Research Fellow, College Lecturer In Biochemistry and various postdocs at the University of Oxford (2013-15). Working on DNA replication, genome integrity and transcription factors in human cancers (and also in prokaryotes). Additional interests in phylogenomics and novel protein expression systems.
Corey Nislow
Corey Nislow's laboratory develops and uses cutting edge tools to address this central question: how can we understand the biological commonalities in all of the life sciences; from embryonic development, to the spread of infectious diseases to better ways to treat cancer. Each of these disciplines can be explained in the context of competition, interaction and evolution. His lab studies the interface between genes and the environment using parallel genome-wide screens, high throughput cell-based assays and next generation sequencing. Most recently, he and his scientific partner, Dr. Guri Giaever, are exploring how laboratory experiments can co-opt evolutionary processes to understand drug action. He enjoys teaching all aspects of biotechnology, genomics and drug discovery. He got his PhD from the University of Colorado, worked at several Biotechnology companies and was at Stanford and University of Toronto before joining UBC in 2013. He has published 161 papers and run 19 marathons.
Sonia MR Oliveira
Doctor Sonia Oliveira holds a Licenciatura in Biology (pre-Bologna) and a Master in Cellular and Molecular Biology from the University of Aveiro, where she also specialized in medicinal plants, toxicology, murine models, and spermatogenesis. In 2011 she moved to Australia to work in Reproductive Biological Sciences. She later explored the nerve-cancer connection in Cancer, namely in female cancers, and completed her Ph.D. in Human Physiology ( with a significant component in Medical Biochemistry and Neurophysiology) from the University of Newcastle (Australia) in 2018. She then worked with biomimetic systems and nanotechnology in diabetes and stem cells. She explored multiple methods for primary and secondary cell culture, always with a keen interest in histopathology, cell biology, and rare disorders. Participated in >40 event(s). (Co-)Supervised MSc dissertation(s) and final projects for course completion of LSc/BSc. And works mostly in the area(s) of Natural sciences with emphasis on Molecular and Cellular Biology, and Medical and Health Sciences with emphasis on Neurosciences, Cancer, Reproduction, Toxicology, Biotechnology, and Stem cells. Also has collaborations in Microbiology, Biomaterials, and Communication and Information technologies.
Jiangjiang Qin
Dr. Jiangjiang Qin is currently a Professor of Cancer Pharmacology and Drug Discovery at the Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences and the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital).
Dr. Qin received his B.S. degree in Pharmacy (2006) and Ph.D. in Biomedical Engineering with the highest honor (2011) from Shanghai Jiao Tong University, China, under the supervision of Professor Wei-Dong Zhang. After completion of Post-Doctoral training in cancer biology, pharmacology, and molecular therapeutics at Texas Tech University Health Sciences Center (TTUHSC) in 2014, Dr. Qin continued his research work at TTUHSC as a Research Associate and a Senior Research Associate and at the University of Houston as a Senior Research Scientist. Dr. Qin joined Zhejiang Chinese Medicinal University as a Full Professor in 2018 and then moved to IBMC in 2020.
Dr. Qin’s research mainly focuses on the discovery and development of novel, effective, and safe anticancer agents as well as demonstrating the molecular targets and mechanisms of action. He has published more than 150 research papers and reviews. He is also an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology and an Editorial Board Member of more than 10 scientific journals such as Recent Patents on Anti-Cancer Drug Discovery, Journal of Cancer Research Updates, World Journal of Traditional Chinese Medicine.
Guangdong Yang
Dr. Yang’s research focuses on a group of gasotransmitters, especially H2S, in the regulation of cellular functions and human diseases. Dr. Yang has received numerous awards and recognitions, including New Investigator award from the Heart and Stroke Foundation of Canada and Maureen Andrew Award from Heart and Stroke Foundation of Ontario. In his career, Dr. Yang has published ~100 peer-reviewed research articles, some of them published in high-impact journals, including as Science, Circulation, PNAS, and EMBO report etc. Their total citations are 7,481 (September 24, 2018).